Related Experiment Videos
[Clinical study on ivermectin against 125 strongyloidiasis patients]
1First Department of Internal Medicine, Faculty of Medicine, University of Ryukyus.
Summary
Ivermectin effectively treats strongyloidiasis in 86.4% of patients with mild side effects. A second ivermectin course eradicated the infection in resistant cases, suggesting its superiority over other drugs.
Area of Science:
- Infectious Diseases
- Parasitology
- Clinical Pharmacology
Background:
- Strongyloidiasis is a parasitic infection caused by Strongyloides stercoralis.
- Effective treatment options are crucial for managing strongyloidiasis.
- Previous studies have investigated various antihelminthic drugs with varying efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of oral ivermectin in treating strongyloidiasis.
- To compare ivermectin's effectiveness against other antihelminthic drugs.
- To identify factors associated with treatment resistance.
Main Methods:
- A study involving 125 patients diagnosed with strongyloidiasis.
- Treatment administered: two oral doses of ivermectin (6 mg) at a 2-week interval.
- Monitoring of eradication rates, side effects, and relevant serological markers (anti-HTLV-I, IgE, eosinophils).
Main Results:
- An overall eradication rate of 86.4% was achieved after the initial treatment course.
- A further course of ivermectin successfully eradicated the parasite in 8 resistant patients.
- Mild, self-limiting side effects were observed in a small percentage of patients; liver dysfunction was noted but asymptomatic.
- Higher anti-HTLV-I antibody positivity was observed in the resistant group compared to the eradicated group.
Conclusions:
- Ivermectin is a highly effective and safe drug for treating strongyloidiasis.
- It demonstrates superior efficacy compared to thiabendazole, mebendazole, and albendazole.
- Anti-HTLV-I antibody status may be associated with treatment resistance in strongyloidiasis.